|
|
N = 25 |
N = 36 |
N = 61
|
| Median age (extremes) |
57 (29–79) |
47 (18–86) |
53 (18–86)
|
| Sex ratio (F/M) |
1.8 |
3 |
2.27
|
|
Clinical characteristics N (%)
|
|
|
|
| Neurological symptoms |
7 (28)
|
22 (61.1)
|
29 (47.5)
|
| Motor deficit/palsy/hemiparesis |
2 |
16 |
18
|
| Seizure |
2 |
6 |
8
|
| Speech disturbance |
0 |
9 |
7
|
| Cognitive impairment |
3 |
3 |
6
|
| Brain abscess |
4 |
1 |
5
|
| Behavioral changes |
0 |
2 |
2
|
| Ocular symptoms |
14 (56)
|
10 (27.8)
|
24 (39.3)
|
| Decreased vision |
12 |
10 |
22
|
| Retinochoroiditis |
6 |
7 |
13
|
| Uveitis/vitritis |
8 |
3 |
11
|
| Necrotizing retinitis |
0 |
4 |
4
|
| Floaters |
1 |
2 |
3
|
| General symptoms |
8 (32)
|
14 (38.9)
|
22 (36)
|
| Fever |
6 |
13 |
19
|
| Headache |
0 |
7 |
7
|
| Asthenia |
2 |
2 |
4
|
| Lymph nodes/Splenomegaly |
1 |
1 |
2
|
| Pulmonary symptoms |
3 (12) |
3 (8.3) |
6 (9.8)
|
| Dermatological signs |
2 (8) |
2 (5.5) |
4 (6.5)
|
| Join synovitis |
0 (0) |
1 (2.8) |
1 (1.6)
|
|
Toxoplasmosis clinical form N (%)
|
|
|
|
| Cerebral |
7 (28) |
23 (63.9) |
30 (49.2)
|
| Ocular |
11 (44) |
8 (22.2) |
19 (31.1)
|
| Disseminated |
4 (16) |
4 (11.1) |
8 (13.1)
|
| Pauci-symptomatic |
3 (12) |
1 (2.8) |
4 (6.6)
|
|
Toxoplasmosis classification N (%)
|
|
|
|
| Definite |
22 (88) |
26 (72.2) |
48 (78.7)
|
| Probable |
3 (12) |
10 (27.8) |
13 (21.3)
|
|
Toxoplasmosis type of infection N (%)
|
|
|
|
| Reactivation |
12 (48) |
19 (52.8) |
31 (50.9)
|
| Primary infection |
10 (40) |
11 (30.5) |
21 (34.5)
|
| Not determinate |
3 (12) |
6 (16.7) |
9 (14.6)
|
|
Diagnostic methods
|
|
|
|
| Serological test + PCR + medical imaging |
12 (48) |
7 (19.4) |
19 (31.1)
|
| Serological test + medical imaging |
1 (4) |
8 (22.2) |
9 (14.7)
|
| Serological test + histology + medical imaging |
0 (0) |
7 (19.4) |
7 (11.5)
|
| Serological test + PCR |
5 (20) |
0 (0) |
5 (8.2)
|
| PCR + medical imaging |
3 (12) |
2 (5.6) |
5 (8.2)
|
| Serological test + PCR + histology + medical imaging |
1 (4) |
3 (8.3) |
4 (6.6)
|
| Histology + medical imaging |
0 (0) |
4 (11.1) |
4 (6.6)
|
| Serological test |
2 (8) |
1 (2.8) |
3 (4.9)
|
| Serological test + histology |
0 (0) |
2 (5.6) |
2 (3.3)
|
| PCR + histology + medical imaging |
1 (4) |
1 (2.8) |
2 (3.3)
|
| Serological test + culture + PCR |
0 (0) |
1 (2.8) |
1 (1.6)
|
|
Treatment N(%)
|
|
|
|
| Pyrimethamine-Sulfadiazine |
10 (40) |
16 (44.5) |
26 (42.6)
|
| Sulfamethoxazole-Trimethoprim |
0 (0) |
9 (25) |
9 (14.8)
|
| No treatment |
3 (12) |
5 (13.9) |
8 (13.1)
|
| Pyrimethamine-Azithromycin |
7 (28) |
0 (0) |
7 (11.5)
|
| Pyrimethamine-Clindamycin |
1 (4) |
3 (8.3) |
4 (6.6)
|
| Pyrimethamine |
0 (0) |
3 (8.3) |
3 (4.9)
|
| Not specified |
2 (8) |
0 (0) |
2 (3.3)
|
| Pyrimethamine-Sulfadiazine-Azithromycin |
1 (4) |
0 (0) |
1 (1.6)
|
| Azithromycin |
1 (4) |
0 (0) |
1 (1.6)
|
|
Outcome N(%)
|
|
|
|
| Recovery |
9 (36) |
22 (61.1) |
31 (50.8)
|
| Partial recovery |
9 (36) |
4 (11.1) |
13 (21.3)
|
| Died |
2 (8) |
7 (19.5) |
9 (14.8)
|
| Not specified |
5 (20) |
3 (8.3) |
8 (13.1)
|
